ICD-10 C44.90: Unspecified Malignant Neoplasm of Skin — Mohs Surgery Documentation, Audit Defense & Overlapping-Site Coding Logic

• Why C44.90 Is the Leading Revenue Threat in Mohs Micrographic Surgery

• The Information Gap — What Existing Resources Miss About C44.90 and Mohs LCD Compliance

• Technical Reference: ICD-10 Documentation Standards for C44.90 and C44.92

• Scribing.io Clinical Logic — Handling the Nasal-Ala-to-Cheek SCC in a Medicare Mohs Case

• Stage-to-Map Synchronization: Matching 17311–17312 Units to the Operative Map

• LCD-Specific Prebill Checks: The Final Gate Before Charge Drop

• Overlapping-Site Decision Tree: When C44.8- Replaces C44.90

• Audit Defense Reconstruction: Surviving TPE and SMRC Reviews

• Implementation Checklist for Mohs Practices

C44.90 on a Mohs claim is not a coding oversight. It is a documentation failure with a price tag — typically $1,050 to $3,100 per case, compounding to six-figure recoupment demands when a MAC applies statistical sampling across a 36-month lookback window. Every Mohs micrographic surgeon who accepts Medicare assignment operates under Local Coverage Determinations that explicitly require anatomic-site specificity, histologic subtype confirmation, and pathology-linked depth documentation. C44.90 satisfies none of these. Scribing.io exists to make this code structurally impossible to submit on a Mohs claim.

This playbook is not a code-lookup reference. CMS already publishes those. What CMS does not publish — and what no competing resource addresses — is the intersection of C44.90 with Mohs-specific LCD audit logic, the overlooked ICD-10-CM overlapping-site convention for cross-subunit lesions, and the documentation pipeline that binds pathology accession data directly into the operative note before charge drop. That pipeline is what Scribing.io delivers. The Scribing.io ICD-10 Documentation Library provides the granular code-level context referenced throughout this guide. See our Mohs Audit-Defense workflow: a live pathology-to-ICD-10 linker that blocks C44.90 at charge drop, enforces H/M/L-zone and overlapping-site rules, and runs LCD-specific prebill checks against 17311–17315.

Why C44.90 Is the Leading Revenue Threat in Mohs Micrographic Surgery

C44.90 encodes a diagnosis that, by definition, lacks the two pillars every MAC auditor evaluates first: anatomic site and histologic cell type. For the Mohs micrographic surgeon, this is not merely a coding inconvenience — it is a direct contradiction of the clinical reality already documented in the pathology report sitting in the same chart.

The Audit Arithmetic

Targeted Probe and Educate (TPE) reviews of Mohs claims focus disproportionately on claims where the ICD-10-CM code is unspecified. The CMS TPE program allows MACs to review up to 40 claims per round, with three rounds before referral to CMS for further action. The financial exposure is immediate:

Auditors do not recoup because the surgery was not performed. They recoup because the documentation submitted alongside the claim does not satisfy the LCD's coverage criteria. C44.90 on a Mohs claim is the functional equivalent of a signed confession that the chart is incomplete. The AMA CPT Editorial Panel structured 17311–17315 to require per-stage documentation precisely because Mohs is a physician-as-surgeon-and-pathologist procedure. An unspecified diagnosis code undermines both roles simultaneously.

The Information Gap — What Existing Resources Miss About C44.90 and Mohs LCD Compliance

Publicly available references for C44.90 — Unspecified malignant neoplasm of skin treat the code as a lookup entry: code description, DRG assignment, and hierarchical context. None address the intersection of C44.90 with Mohs-specific Local Coverage Determinations — the actual documents that govern whether a Mohs claim is paid or recouped.

The Anchor Truth

Auditors recoup Mohs surgery fees for C44.90 if the note doesn't link the code to a specific Anatomic Map and Depth derived from a confirmed pathology report.

This recoupment is not discretionary. Across MAC LCDs for Mohs micrographic surgery (see, for example, CMS Medicare Coverage Database LCD L35091 and its analogues), pairing CPT 17311–17315 with C44.90 triggers recoupment unless the chart includes:

1. A Mohs Anatomic Map identifying High-risk (H), Medium-risk (M), and Low-risk (L) zones per NCCN Clinical Practice Guidelines for Squamous Cell Skin Cancer and the American College of Mohs Surgery consensus definitions.

2. Histologic confirmation with documented depth and perineural invasion status, sourced from the final pathology report and linked to the operative note by pathology accession number.

The Overlapping-Site Rule Most Practices Miss

Here is the nuance that neither CMS code-table pages nor standard coding references address:

When a cutaneous malignancy crosses cosmetic subunits — e.g., nasal sidewall extending into the cheek, or periauricular skin extending into the temple — ICD-10-CM coding conventions require an overlapping-site code (C44.80 through C44.89) rather than the unspecified C44.90. The ICD-10-CM Official Guidelines for Coding and Reporting (Section I.C.2.d) specify that overlapping-site codes should be assigned when a neoplasm overlaps two or more contiguous sites and the point of origin cannot be determined.

The clinical scenario is extremely common in Mohs: a squamous cell carcinoma originating on the nasal ala that, upon serial sectioning, extends beyond the nose anatomic boundary onto the malar cheek. The nose maps to C44.31x; the cheek maps to C44.39x or C44.309. When the origin cannot be assigned to either site alone, the correct code is in the C44.8- overlapping-site family, subcategorized by cell type.

Most EHRs do not prompt for zone classification or overlapping-site logic. The surgeon documents "left nasal ala extending to cheek" in the operative note narrative, but the ICD-10 pick list defaults to the nose or, worse, to C44.90 when the coder cannot determine a single-site code. The result: a compliant narrative coupled with a non-compliant code — the exact combination that triggers TPE review.

Technical Reference: ICD-10 Documentation Standards

Understanding why C44.90 fails audit requires understanding what it encodes — and what the alternative codes encode.

C44.90 — Unspecified Malignant Neoplasm of Skin, Unspecified

• Full descriptor: Unspecified malignant neoplasm of skin, unspecified

• "Unspecified" appears twice: once for cell type (not BCC, not SCC, not Merkel, not melanoma — just "malignant neoplasm") and once for anatomic site (not face, not trunk, not extremity — just "skin").

• Clinical implication: The chart contains no information about what kind of cancer it is or where on the body it is.

• LCD implication for Mohs: A Mohs claim requires site-specific medical necessity. An unspecified site code cannot demonstrate that the lesion is in an H-zone (periorbital, nasal, periauricular, lip) or any other area where Mohs is the appropriate technique per published evidence in PubMed-indexed literature. Automatic coverage failure.

For a complete reference, see C44.90 — Unspecified malignant neoplasm of skin.

C44.92 — Squamous Cell Carcinoma of Skin, Unspecified

• Full descriptor: Squamous cell carcinoma of skin, unspecified; C44.92 — Squamous cell carcinoma of skin

• Improvement over C44.90: Cell type is specified (SCC). This satisfies one of the two LCD requirements — histologic confirmation.

• Remaining gap: Site is still "unspecified." The MAC still cannot confirm the lesion is in a location where Mohs is medically necessary per LCD criteria. This code alone will still fail most Mohs-specific audits unless the operative note, pathology report, and Mohs map collectively document the site to the cosmetic-subunit level.

Quick-Reference Hierarchy: From Non-Compliant to Fully Compliant

The principle: every step toward specificity is a step away from recoupment. Scribing.io enforces maximum specificity by cross-referencing the pathology DiagnosticReport cell-type field with the operative map site field and selecting the most granular code the clinical data supports. When specificity data is missing, the system halts charge drop and routes the note back to the surgeon — it never defaults to unspecified codes.

Scribing.io Clinical Logic — Handling the Nasal-Ala-to-Cheek SCC in a Medicare Mohs Case

This section walks through the exact clinical scenario where C44.90 causes a $3,100 recoupment — and how Scribing.io's automated documentation pipeline prevents it at every decision node.

The Scenario

A 68-year-old Medicare patient undergoes Mohs micrographic surgery for squamous cell carcinoma involving the nasal ala extending onto the cheek. The claim is submitted with C44.90 and no Mohs anatomic map or linked pathology depth. During TPE, the MAC cites missing zone mapping and unspecified diagnosis, recouping $3,100 for CPT 17311–17312.

Why the Claim Failed: Root-Cause Decomposition

The Scribing.io Pipeline: Step-by-Step Audit-Proof Documentation

Step 1 — Pathology DiagnosticReport Ingestion. The system ingests the final pathology DiagnosticReport via HL7 FHIR R4 DiagnosticReport resource or legacy ORU^R01 message. It extracts five structured fields: accession number (e.g., S26-04872), histologic diagnosis (squamous cell carcinoma, infiltrative subtype), invasion depth (to subcutis), perineural invasion status (present), and margin status (positive — the clinical basis for Mohs referral). This extraction is automatic; no coder intervention is required.

Step 2 — Accession Binding. The pathology accession ID is injected into the operative note template as a locked, non-editable field. The surgeon's dictation now reads: "Pathology confirmed SCC, infiltrative subtype, with perineural invasion and depth to subcutis (accession S26-04872)." This creates a traceable, auditable link between the diagnosis and the surgical record — the exact linkage the MAC auditor will look for during TPE. Per JAMA Dermatology audit-preparedness recommendations, accession-level traceability is the gold standard for Mohs documentation integrity.

Step 3 — Histologic Risk-Term Extraction. Scribing.io's NLP layer identifies the terms infiltrative, morpheaform, perineural invasion, and depth to subcutis as high-risk features per NCCN Clinical Practice Guidelines for cutaneous squamous cell carcinoma. These features are surfaced to the surgeon in a pre-sign review panel, confirming Mohs medical necessity. The system generates a structured Medical Necessity Justification block that reads: "Mohs micrographic surgery is indicated per NCCN Guidelines: infiltrative histologic subtype with perineural invasion; lesion located in H-zone (nasal ala); depth of invasion to subcutis."

Step 4 — Anatomic Map Enforcement (H-Zone Detection). The system requires the surgeon to complete a Mohs anatomic map before the note can be finalized. This is a hard gate — no map, no signature release. The map interface:

• Places the lesion on the nasal ala, which the system automatically classifies as H-zone per the NCCN/ACMS risk-zone consensus schema

• Identifies extension onto the malar cheek via the surgeon's marking of tumor boundaries across the nasolabial fold

• Flags the cross-boundary condition and presents the surgeon with a confirmation prompt: "Tumor crosses nasal ala → cheek boundary. Overlapping-site code C44.82 will be applied per ICD-10-CM Section I.C.2.d. Confirm or override."

Step 5 — Overlapping-Site ICD-10 Substitution. Upon surgeon confirmation of cross-boundary spread, Scribing.io replaces the default code. The logic chain:

1. Pathology cell type = SCC → eliminates C44.90 (unspecified type), eliminates C44.81 (BCC overlapping)

2. Anatomic site = nasal ala (C44.31x) + cheek (C44.39x) → two classified sites, neither predominates

3. ICD-10-CM overlapping-site convention triggered → C44.82 (squamous cell carcinoma of overlapping sites of skin)

4. C44.90 is hard-blocked from the claim. It cannot be manually re-entered without a compliance override that generates an audit trail.

Stage-to-Map Synchronization: Matching 17311–17312 Units to the Operative Map

MAC auditors count stages on the Mohs map and compare them to the CPT units billed. A mismatch — two stages billed but only one documented on the map, or stages documented without orientation markers — triggers immediate recoupment of the excess units. This is the second most common Mohs audit failure after unspecified diagnosis coding.

Scribing.io enforces stage-to-map synchronization through a bidirectional counter:

The stage counter is not overridable without a documented clinical justification. If a surgeon bills three stages but the map shows two, the system will not release the third-stage charge until the map is updated or an attestation is entered explaining the discrepancy (e.g., tissue block processed from a mapped but unlabeled orientation).

LCD-Specific Prebill Checks: The Final Gate Before Charge Drop

Before any Mohs charge reaches the clearinghouse, Scribing.io runs the claim against a MAC-specific LCD rule engine. The checks are not generic — they are mapped to the specific LCD article governing Mohs micrographic surgery for the patient's MAC jurisdiction (e.g., Novitas L35091, NGS L37020, Palmetto L35698). The engine validates:

This prebill engine is the mechanism by which Scribing.io achieves what no standard EHR offers: LCD compliance verification at the point of documentation, not after claim denial.

Overlapping-Site Decision Tree: When C44.8- Replaces C44.90

The overlapping-site determination is one of the most under-documented coding decisions in dermatologic surgery. Scribing.io automates it, but surgeons and coders should understand the logic. The decision tree follows ICD-10-CM Official Guidelines Section I.C.2.d:

1. Is the tumor confined to a single ICD-10-CM anatomic site?

   • Yes → Assign the site-specific code (e.g., C44.321 for SCC of nose)

   • No → Proceed to step 2

2. Does the tumor cross into a contiguous, separately classified ICD-10-CM site?

   • Yes → Proceed to step 3

   • No (e.g., two areas within the same ICD-10 site category) → Assign the site-specific code for the broader category

3. Can the site of origin be determined?

   • Yes → Assign the code for the site of origin (per ICD-10-CM convention, the originating site takes precedence)

   • No → Assign the overlapping-site code: C44.81 (BCC), C44.82 (SCC), C44.89 (other specified), or C44.80 (unspecified type, overlapping)

4. Never assign C44.90 when an overlapping-site code is available. C44.90 is "unspecified site," which implies no site information exists. If the surgeon documents tumor in two named sites, site information does exist — it just spans a boundary. That clinical fact maps to C44.8-, not C44.90.

Scribing.io encodes this decision tree in its code-selection engine. When the Mohs map shows tumor crossing a subunit boundary, the system skips C44.90 entirely and presents C44.8- codes filtered by pathology-confirmed cell type. The surgeon never sees C44.90 as an option in this workflow.

Audit Defense Reconstruction: Surviving TPE and SMRC Reviews

When a MAC or the Supplemental Medical Review Contractor (SMRC) requests records for a Mohs claim, the documentation package must tell a self-contained story. Scribing.io generates an Audit Defense Bundle that includes:

• Operative note with embedded pathology accession number, structured Medical Necessity Justification block, and H/M/L zone classification

• Mohs anatomic map with per-stage tissue block orientation, margin status per stage, and final clear-margin confirmation

• Pathology report (original, linked by accession ID) showing histologic subtype, depth of invasion, perineural invasion status, and margin status of the biopsy specimen that triggered Mohs referral

• ICD-10 code derivation trail showing the logic chain: pathology cell type (SCC) + map sites (nasal ala + cheek) + overlapping-site convention = C44.82

• LCD compliance checklist auto-populated at the time of charge drop, showing each LCD element was satisfied before the claim was released

This bundle is generated automatically. The surgeon does not need to reconstruct documentation months after the procedure. Per HHS Office of Inspector General guidance on medical record integrity, contemporaneous documentation created at or near the time of service carries significantly more weight in audit proceedings than after-the-fact attestations.

Reprocessing the Failed Scenario

Returning to the 68-year-old Medicare patient with SCC of the nasal ala extending to the cheek: with Scribing.io in place, the claim submitted to the MAC contains C44.82 (not C44.90), supported by a Mohs map showing H-zone involvement and cross-boundary extension, linked to pathology accession S26-04872 confirming infiltrative SCC with perineural invasion and depth to subcutis. CPT 17311 and 17312 match the two documented stages on the map. The LCD prebill engine confirmed all elements before charge drop. When the MAC selects this claim for TPE, the auditor opens a documentation package that answers every question before it is asked. Result: claim sustained, $3,100 preserved.

Implementation Checklist for Mohs Practices

Deploy these operational changes to eliminate C44.90 from your Mohs claim stream:

C44.90 is not a code your practice should ever submit on a Mohs claim. It is a documentation deficit made visible — a signal to every auditor that the chart lacks the site specificity, histologic confirmation, and pathology linkage that Mohs micrographic surgery inherently produces. The clinical data exists. The pathology report contains it. The operative map depicts it. The failure is in the pipeline that connects those elements to the claim. Scribing.io is that pipeline: it ingests the pathology, enforces the map, applies overlapping-site logic, synchronizes stages, and runs LCD checks — all before the charge drops. The $3,100 recoupment in the scenario above was entirely preventable. Every C44.90 on a Mohs claim is.